Immunoepigenetics: the unseen side of cancer immunoediting

被引:15
作者
Germenis, A. E. [1 ]
Karanikas, V. [1 ]
机构
[1] Univ Thessaly, Dept Immunol & Histocompatibil, Univ Hosp Larissa, Sch Med, GR-41110 Larisa, Greece
关键词
epigenetic drugs; DNA methylation; immune escape; immunoepigenetics; immunoediting; immunosurveillance;
D O I
10.1038/sj.icb.7100006
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cancer immunosurveillance representing, till recently, the explanatory framework relating cancer and the immune system, does not convincingly explain tumor escape. At the beginning of the decade, a new theory emerged, namely the immunoediting theory, and it comprehensively defines the role of the immune system in carcinogenesis. The core of this theory embraces the concept that the immune system on the one hand protects the body from cancer and on the other it shapes the immunogenicity of these cancers, thus presents a persuasive rationalization of the resistance of tumors against the immune response. With the immune system playing, in this context, such a pivotal role in shaping the tumor immune profile and in subsequent oncogenesis, it seems rather paradoxical to accept the immunocompetent host's immune system as a constant moiety. While DNA mutations of immune genes create a rather polymorphic condition, their frequency is much lower than that of other genetic events. Of these, epigenetic alterations give rise to new epialleles, which can reach up to 100% per locus. Bearing in mind that cancer is characterized by a tremendous amount of epigenetic aberrations, in both gene and global level, it is reasonable to postulate that, for the same unknown causes, analogous aberrations could affect the immune genes. Should this be the case, the relation between oncogenesis and the immune system appears much more dynamic and complex. Such an immunoepigenetic approach to carcinogenesis could improve our understanding of a series of common cancer-related aspects, such as environmental risk factors, effectiveness of demethylating agents, failure of current immunotherapies, etc. Moreover, this immunoepigenetic paradigm will take the current perception of the immune system and cancer interrelation further and beyond, constituting that the immunoresistant cancer cell phenotype is not shaped by the immune system acting as a steady and rigid evolutionary pressure, but rather as an extremely dynamic variable.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 74 条
[1]   Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies [J].
Abu-Shakra, M ;
Buskila, D ;
Ehrenfeld, M ;
Conrad, K ;
Shoenfeld, Y .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (05) :433-440
[2]  
Asano Y, 2001, ANN HEMATOL, V80, P634
[3]  
Ballaz Santiago, 2003, Clin Lung Cancer, V5, P46, DOI 10.3816/CLC.2003.n.021
[4]   Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer [J].
Belinsky, SA .
CARCINOGENESIS, 2005, 26 (09) :1481-1487
[5]   Mutations and regulatory anomalies effecting tumor cell immune functions [J].
Blanck, G .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (01) :1-16
[6]   Evidence for immune defects in breast and lung cancer patients [J].
Caras, I ;
Grigorescu, A ;
Stavaru, C ;
Radu, DL ;
Mogos, I ;
Szegli, G ;
Salageanu, A .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (12) :1146-1152
[7]  
Carbone Michele, 2004, Cancer Res, V64, P5518, DOI 10.1158/0008-5472.CAN-04-0255
[8]   Human tumor-specific T lymphocytes: does function matter more than number? [J].
Coulie, PG ;
Connerotte, T .
CURRENT OPINION IN IMMUNOLOGY, 2005, 17 (03) :320-325
[9]   Rational approaches to human cancer immunotherapy [J].
Davis, ID ;
Jefford, M ;
Parente, P ;
Cebon, J .
JOURNAL OF LEUKOCYTE BIOLOGY, 2003, 73 (01) :3-29
[10]  
DOERFLER W, 1995, CURR TOP MICROBIOL, V197, P209